In ocular surface inflammatory diseases, such as dry eye disease, long-term symptom relief requires targeting the inflammation itself rather than treating only the surface-associated dryness with artificial tears. Therefore, we included an anti-inflammatory agent in an unpreserved liposome-based (LP) formulation used as artificial tears. Our aim was to characterize and study its in vitro and ex vivo cell uptake and functionality. Human corneal epithelial (HCE) cells were used to study MPA-LP-induced effects after 60 min of exposure, using blank LP and non-LP MPA formulations as controls. A fluorescent labeled LP formulation was used to determine uptake by HCE cells and localization in ex vivo porcine corneas. The LP formulation complied with the required physicochemical properties and had no cytotoxicity on HCE cells after 60 min of exposure. HCE cells showed LP-associated fluorescence at 24, 48, and 72 h after 60 min of exposure, and the LP-associated fluorescence was uniformly distributed throughout the porcine corneal epithelium immediately after 5 min of exposure. MPA-LP increased protein expression and nuclear translocation of progesterone receptor in comparison with controls as determined by Western blotting and immunofluorescence. Moreover, MPA-LP significantly reduced the cell proliferation rate and IL-6 and IL-8 production 48 h after the exposure period, as determined by the alamarBlue assay and ELISA, respectively. None of these effects were evident in blank LP-exposed cells and non-LP MPA formulation reduced only IL-6 production. Our results suggest that the LP-based formulation, used to replenish the lipids of the tear film, can be loaded with anti-inflammatory agents that can be delivered into the cells and activate specific drug receptors. These agents can reduce inflammatory cytokine production and may be effective in the treatment of inflammatory processes associated with ocular surface diseases.
Introduction
Eye tissues are affected by diverse inflammation-based diseases that can be devastating as eyesight is impaired. A paradigm of such inflammatory disorders is dry eye disease (DED), a common agerelated ocular pathology that results from dysfunction of the ocular surface and/or tissues that produce the tears. The primary effects of patients with DED are impaired functional visual acuity and low quality of life. At the molecular level, the main reason of these effects is an underlying inflammation process that profoundly alters the ocular surface tissues and the tear film. Recent research has led to innovations in the pharmacological treatment of DED. These advances have focused on tear replacement or tear preservation with novel artificial tears, topical and systemic antiinflammatory and immunosuppressive therapy, and even the use of medical devices in the more severe grades of the disease (Pflugfelder et al., 2000) . Despite significant progress in these treatments, the disease in many patients is not fully alleviated. Although current treatments with artificial tears are the first step for symptomatic relief, the ongoing inflammation is not addressed. The use of drug delivery systems is of great interest to improve the pharmacological management of DED because they can encapsulate active agents, direct them to the target tissue/cells, and release the cargo in a controlled fashion (Diebold and Calonge, 2010; Patel et al., 2013) . In topically administered drugs, these devices overcome drawbacks such as low bioavailability due to the tear film barrier, rapid drainage, and poor corneal permeation.
Among drug delivery systems, liposomes (LPs), which are vesicles containing an aqueous core and delimited by a membrane-like lipid bilayer, ensure good biological compatibility and reduced toxicity. The existence of an aqueous core and the lipid bilayer confers the ability to encapsulate both hydrophilic and lipophilic compounds with improved drug stability. LPs have been employed to improve drug transport across the cornea (Di Tommaso et al., 2012) with prolonged drug effect (Hathout et al., 2007; Law et al., 2000) . The idea of using LPs as carriers for topically administered anti-inflammatory drugs was first reported in 1982 (Schaeffer and Krohn, 1982) and has been continuously revised (Lim et al., 2015) . Corticosteroids are potent anti-inflammatory agents, poorly soluble in aqueous solution, which makes them good candidates for being encapsulated in drug delivery systems. However, with prolonged treatment, the potent activity of these drugs often causes adverse effects, such as increased intraocular pressure or cataract formation. For this reason, synthetic "soft" anti-inflammatory steroids, like medroxyprogesterone acetate (MPA), are frequently prescribed for topical administration in the eye.
Taking all of this information into account, our aim was to prepare and characterize a LP-based formulation loaded with the anti-inflammatory agent MPA that could be used as topically instilled artificial tears. Prior to proceeding with in vivo studies, it was necessary to determine by in vitro studies how corneal epithelial cells take up the drug delivery system and the encapsulated drug. Then, we asked whether or not the encapsulated drug was delivered into the cells and activated glucocorticoid and progesterone receptors, eliciting an anti-inflammatory effect in an in vitro inflammation model of human corneal epithelial cells.
Materials and methods

Materials and equipment
All materials used in this study were purchased from SigmaAldrich (St. Louis, MO) except as follows: Phospholipon 90G, >95% of phosphatidylcholine (PC), was purchased from Lipoid GmbH (Cologne, Germany) and trehalose was acquired from Cymit Química S.L. (Barcelona, Spain 
Liposomal formulation preparation and fluorescent labeling
LP formulation composed of PC, cholesterol, vitamin E, and MPA at a molar ratio 13:3:0.2:0.3 was prepared by the solvent evaporation technique as previously described (Vicario-de-la-Torre et al., 2014) . The film formed was hydrated with a dispersion solution comprised of borate buffer solution (135.5 mM) containing trehalose (42.5 mM). The MPA-LP formulations were extruded through a size-controlled 0.22-mm pore size polycarbonate membrane for ten cycles under nitrogen pressure ( 200 psi) to obtain lipid vesicles with a unimodal size distribution. Final PC and MPA concentrations in the resultant dispersion were 20 mg/mL and 200 mg/mL, respectively.
To obtain fluorescently-labeled LP formulation, the lipid mixture containing coumarin-6 (C6) instead of MPA was dissolved in chloroform, and the C6-LP formulation was obtained following the protocol described above. Fluorescent C6-LP at a final C6 concentration of 20 mg/mL was used in human corneal epithelial (HCE) cells and ex vivo porcine corneas (see sub-section 2.6 below). To determine LP-associated fluorescence, a suspension of C6 (not in liposomes) obtained from the supernatant after C6-LP centrifugation (49,263 g for 60 min at 10 C) was used as the control. Particle size distribution of blank, MPA-, and C6-LP formulations were measured by dynamic light scattering using a particle size analyzer at room temperature.
To determine the encapsulation efficiency, the LP formulation was centrifuged (49,263 g for 60 min at 10 C), and the supernatant was then analyzed by HPLC at 40 C. Isocratic MPA analysis was performed with a mobile phase of acetonitrile/tetrahydrofurane/ ultrapure milliQ water (45/10/45), a flow rate of 1 mL min
À1
, and detection at 254 nm. The retention time was 12.5 min. This analytical procedure, described in Pharmacopeia (Shabir, 2003) , was previously validated in our laboratory with regard to linearity, precision, and accuracy parameters. Encapsulation efficiency (EE) was calculated as follows:
where C0 and C1 were the concentration of the drug in the LP dispersion and in the supernatant after centrifugation.
pH, osmolarity, and viscosity measurements
The pH of the MPA-and C6-LP formulations was measured using a pH meter in triplicate at room temperature.
Osmolarity was analyzed by a vapor pressure osmometer and performed in triplicate at 33 C, equivalent to the ocular surface temperature (Purslow and Wolffsohn, 2005) .
Viscosity was measured using a thermostatically controlled rheometer. Viscosity was measured when the steady state was reached with shear rates increasing from 0 to 1000 s
À1
. All determinations were made in triplicate at 33 C.
Culture conditions and liposomal formulation exposure
The HCE cell line (Araki-Sasaki et al., 1995) was cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum, 5000 U/mL penicillin/streptomycin, 10 ng/mL human epidermal growth factor, and 5 mg/mL insulin. Cells from passages 32 to 38 were used.
Cells were grown until confluence and washed in supplementfree culture medium. Then, the LP formulations were diluted in supplement-free culture medium to get a final PC concentration of 5 mg/mL and added to the cultured cells for 60 min. A MPAcommercial formulation was used as anti-inflammatory non-LP reference formulation (Medrivas ® ), and unexposed cells or cells exposed to the dispersion solution and blank LP formulation were used as controls. After the exposure period, the cells were washed 3 times in phosphate buffered saline (PBS) and fresh serum-free culture medium was added.
Cytotoxicity assay
To measure potential formulation toxicity, the XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) cytotoxicity assay was used. After the exposure period, the XTT reagent was added according to manufacturer's instructions and absorbance read. At least 3 independent experiments in triplicates were performed. Benzalkonium chloride (BAC) at 0.001% was used as positive cytotoxicity control. The percentage of viable cells relative to control cells was determined.
Liposomal formulation uptake by HCE cells and localization in ex vivo porcine corneas
The C6-LP was quantified and localized by fluorometry and fluorescence microscopy, respectively. To ensure that the fluorescence originated from C6-LP, a C6 suspension was used as the control. For fluorometry determinations, HCE cells were plated in black 96-well plate and exposed to C6-LP or C6 suspension (not in liposomes) for 60 min. Then, cells were washed with PBS until the fluorescent signal of the PBS used for washing cells was the same that fresh PBS. The fluorescent signal (excitation wavelength: 490 nm; emission wavelength: 520 nm) of the bottom of each well was measured at 0, 24, 48, and 72 h after the exposure period. Unlabeled LP formulation in PBS was used as a blank. For fluorescence microscopy, HCE cells were plated in multichambered coverslip and exposed to C6-LP or C6 suspension for 60 min and over washed. Representative micrographs were taken at each time point using same optimized exposure time, gain, and intensity of the camera. Also, cell uptake was further characterized immediately after the exposure period. Cell nuclei were counterstained with Hoechst dye and vertical spatial images were generated by Zscans. At least 3 independent experiments in triplicates were performed.
In addition, ex vivo porcine corneas were used to localize the LP formulation in the stratified corneal epithelium and stroma. Porcine eyeballs (n ¼ 3), obtained from a local slaughterhouse, were washed with povidone iodine solution and PBS. Then, a 12-mm diameter silicon ring was placed on the central cornea, and a C6-LP or C6 suspension (not in liposomes) was applied for 5 and 60 min. Unlabeled blank LP formulation at the same exposure period was used as control. After the exposure, the eyeballs were washed with PBS and placed in 2.5% buffered paraformaldehyde. The central cornea was isolated and embedded in optimal cutting temperature compound and frozen. Representative micrographs of cryostat sections (5 mm) were taken using the same optimized exposure time, gain, and intensity for each group of samples. At least 3 independent experiments were performed.
Protein expression analysis by electrophoresis and Western blotting
Cells were homogenized in ice-cold radioimmunoprecipitation assay buffer plus protease inhibitors, and the protein content was quantified. Total protein was heated at 100 C, and 15 mg of protein from each sample was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Proteins were subsequently transferred to nitrocellulose membranes, and incubated with a blocking solution composed of tris-buffered saline containing 0.05% Tween-20, 5% powdered milk, and 2.5% bovine serum albumin for 60 min. The membranes were incubated with 2.5 mg/mL of primary antibodies in blocking solution overnight at 4 C and with peroxidase-conjugated secondary antibodies for 60 min. Receptor protein expression was normalized to GAPDH expression. At least 3 independent experiments in duplicates were performed.
Glucocorticoid receptor and progesterone receptor localization by immunofluorescence analysis
Some HCE cultures were fixed in ice-cold methanol immediately after exposure to the liposomal formulations and kept at À20 C while others were fixed 24 h after LP exposure. Slides were washed in PBS and incubated with 0.3% Triton X-100 for 10 min. The slides were incubated at room temperature for 60 min in PBS with 4% donkey serum. They were then incubated with 5 mg/mL of primary antibodies against glucocorticoid and progesterone receptors overnight at 4 C. Alexa Fluor 488-conjugated secondary antibody was incubated for 60 min at room temperature. Cell nuclei were counterstained with propidium iodide. Negative controls omitted the primary antibodies (isotype control). Micrographs were taken using the same optimized exposure time, gain, and intensity of the camera. To calculate percentage of nuclear receptor fluorescence, green (receptor) and red (nuclei) channels were thresholded. The percentage of nuclear translocation was calculated using the following formula:
where the receptor fluorescence (green) localized in the nuclear area (demarcated by red) were the mean grey value of the thresholded green channel under the thresholded red channel and the total receptor fluorescence was the mean grey value of the thresholded green channel. The values were obtained from 4 independent experiments.
Cell proliferation assay
To determine possible changes in cell proliferation rate by MPA-LP exposure, the alamarBlue ® cell proliferation assay was performed at 24, 48, and 72 h after the exposure period. Fluorescence was read according to manufacturer's instructions. At least 3 independent experiments in duplicates were performed. The percentage of proliferation in treated cultures compared with values for untreated control cells at 24 h was determined.
In vitro inflammation model
To determine if MPA-LP induced an anti-inflammatory response in HCE cells, an in vitro inflammation model was used as previously described (Enriquez-de-Salamanca et al., 2008) . Briefly, HCE cells were stimulated with 25 ng/mL TNFa for 24 h after a washing period with supplement-free culture medium. The cells were then exposed to blank LP, MPA-LP, and the reference formulation (Medrivas ® ). The cells were washed with PBS and fresh medium was added. Cell supernatants were collected 48 h after the exposure period, and IL-6 and IL-8 production quantified with human IL-6 and IL-8 ELISA kits according to manufacturer's instructions. At least 3 independent experiments in duplicates were performed. The ratio of each interleukin concentration to number of cells was calculated by the alamarBlue ® assay.
Statistical analyses
Data were expressed as means ± standard errors of the mean (SEM). Student's t-test was used to compare two groups. For groups with significantly different variances (F-test), Welch's correction was done. For more than 2 groups, we performed either a one-way analysis of variance followed by pairwise comparisons (Tukey's test) or a Brown-Forsythe test followed by pairwise comparisons (Games-Howell test), depending on Levene's test for homogeneity of variances. Differences were considered to be significant when p 0.05.
Results
Liposomal formulation characterization and biocompatibility
MPA or C6 addition to the LP composition did not change the mean diameter of liposomes (Fig. 1A, Table 1 ). MPA and C6 were included in the initial lipid mixture and passively loaded into the lipid bilayer of the LPs. The encapsulation efficiency was close to 94% and 89%, respectively.
The mean diameter, pH, osmolarity, and viscosity of blank, MPAand C6-LP is shown in Table 1 . The LP-based formulations did not show statistically significant differences in pH, osmolarity, and viscosity compared with the borate-trehalose-buffered LP-free solution (data not shown).
The percentage of viable HCE cells did not differ significantly from untreated cells after 60 min of exposure with either blank, MPA-, or C6-LP (Fig. 1B) . The reference formulation (Medrivas ® ) was well tolerated while the BAC solution caused significant cell death, as expected.
Uptake and localization of LP formulation in vitro by HCE cells and epithelial localization in ex vivo porcine corneas
The cellular fluorescent signal was significantly higher after exposure to the C6-LP than after exposure to the C6 suspension at all times of analysis ( Fig. 2A) . However, C6 suspension can also interact with plasmatic membranes and some fluorescence was detected after sequential cell wash. Z-axis micrographs showed that after C6-LP exposure for 60 min, the fluorescence was located not only in the cell membrane but also intracellularly (Fig. 2B) .
After 5 min of C6-LP exposure, the ex vivo porcine corneas showed fluorescence uniformly distributed throughout the corneal epithelium (Fig. 3) . In contrast, penetration of the C6 suspension was largely limited to the outermost epithelial cells. After 60 min of exposure, the corneal stroma also showed fluorescent signal. However, the C6 suspension-associated fluorescence was weaker and localized only in the outermost corneal epithelial layers, supporting the permeation of the LP formulation through the cornea. There was no fluorescent signal associated with unlabeled LP formulation at any time analyzed.
Effect of MPA-LP and reference formulation (Medrivas
®
) on glucocorticoid and progesterone receptor protein expression in HCE cells
Glucocorticoid and progesterone receptor protein expression did not differ immediately after exposure for 60 min (Fig. 4A) . However, 24 h after exposure, progesterone receptor expression was increased after MPA-LP exposure compared with the control, blank LP-, and reference formulation-exposed cells (Fig. 4B) . At that time point, glucocorticoid receptor expression was decreased in reference formulation-exposed cells compared with control (p ¼ 0.067), blank LP-(p ¼ 0.072), and MPA-LP-exposed cells, although only the latter reached statistical significance (p 0.05).
Effect of MPA-LP on nuclear translocation of glucocorticoid and progesterone receptors in HCE cells
There was no measurable nuclear translocation of the glucocorticoid receptor after exposure for 60 min for any of the LP or reference formulation treatments (Fig. 5A) . However, immediately after the exposure period, nuclear translocation of the progesterone receptor was higher in MPA-LP-exposed cells than in blank LPexposed and untreated cells (Fig. 5B) . Twenty-four hours after the exposure, neither the glucocorticoid receptor nor the progesterone receptor translocation to the nucleus after MPA-LP exposure was evident (data not shown).
Time-dependent effect of MPA-LP on cell proliferation of HCE cells
At 24 h after the exposure period, cell proliferation in MPA-LPexposed cells was significantly decreased compared with untreated control cells. At 48 h, the proliferation of MPA-LP-exposed cells was significantly lower than in blank LP-exposed cells (Fig. 6 ). Differences in cell proliferation disappeared 72 h after the exposure period. 
Effect of MPA-LP on IL-6 and IL-8 production by inflamed HCE cells
Prior to determining the anti-inflammatory effect of MPA-LP, changes in glucocorticoid and progesterone receptors after TNFa stimulation were analyzed by electrophoresis and Western blotting, and immunofluorescence. Cells stimulated with TNFa did not show changes in protein expression or translocation of glucocorticoid and progesterone receptors compared with unstimulated cells (data not shown).
In response to TNFa stimulation for 24 h, the HCE cells increased IL-6 but not IL-8 production 48 h after inflammatory stimulus removal. MPA-LP exposure significantly reduced both basal and TNFa-induced IL-6 production, reaching unstimulated control levels (Fig. 7A) . The reference formulation (Medrivas ® ) also reduced IL-6 production in basal and TNFa-stimulated cells. MPA-LP exposure also significantly reduced IL-8 production compared with the blank LP and reference formulations in TNFa-stimulated HCE cells (Fig. 7B) . Interestingly, blank LP formulation reduced IL-8 production more than did the reference formulation.
Discussion
In this work we report that a LP formulation, loaded with an anti-inflammatory drug, efficiently permeated through corneal epithelial barriers, activated specific drug receptors, and reduced the production of inflammatory cytokines IL-6 and IL-8 in cultured HCE cells. The scarcity of anti-inflammatory drugs in the market drove us to include an anti-inflammatory agent in a LP formulation designed as artificial tears to treat DED (Vicario-de-la-Torre et al., 2014). We selected the anti-inflammatory hormone MPA whose properties make it a good steroid-sparing agent, often used to decrease the dependency of a long-term therapy with steroids in ocular surface inflammatory diseases.
Taking into account the special requirements for topical ophthalmic formulations, i.e., pH ¼ 6e9, osmolarity ¼ 150e320 mOsm, viscosity <20 mPa (Ali and Lehmussaari, 2006; Ammar et al., 2009) , the values of our LPbased formulations (Table 1 ) met all the requirements to be used as eyedrops. The liposomal formulation was comprised of components not only similar to those present in the natural tears, such as PC and cholesterol, but also antioxidants (vitamin E) and molecules able to provide special benefits for the ocular surface (trehalose) (Li Fig. 3 . Localization in ex vivo porcine corneas. C6-LP was uniformly distributed throughout the corneal epithelium in ex vivo corneas after 5 min and 60 min of exposure. Arrows show stromal localization of C6-LP after 60 min of exposure in ex vivo porcine corneas. LP: liposome-based formulation; C6: coumarin-6; C6-LP: liposome-based formulation loaded with C6. Scale bar: 50 mm. Fig. 4 . Changes in the expression of glucocorticoid and progesterone receptors in human corneal epithelial cells. Although no changes were shown immediately after (T 0 h) the exposure period (A), MPA-LP-exposed cells increased progesterone receptor expression compared with control, blank LP, and reference formulation-exposed cells after 24 h (T 24 h) the exposure period (B), as determined by electrophoresis and Western blotting. *P 0.05; **P 0.01. LP: liposome-based formulation; MPA-LP: liposome-based formulation loaded with medroxyprogesterone acetate; GR: glucocorticoid receptor; PR: progesterone receptor; Rs: receptors; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. Pinto-Bonilla et al., 2015) . Also, our liposomal formulation does not contain any preservative, thus avoiding the wellknown harmful side effects associated with them (Baudouin et al., 2010) .
We labeled the LP formulation with C6 to localize it in HCE cells and in ex vivo corneas after 5 and 60 min of exposure. Although the encapsulation efficiency for C6 was always around 90%, free C6 can penetrate through cell membranes. Consequently, we used a C6 suspension as control to distinguish LP-associated fluorescence from that caused by C6 in suspension. How the LPs bind to and are endocytosed by cultured cells has been widely reviewed (Duzgune et al., 1999 , Lee et al., 1993 . LP composition, charge, and size, as well as the types of cells to which they are exposed, influence the cellular uptake. Therefore, we analyzed cellular uptake of the LP formulation by HCE cells. It is important to point out that serum was avoided in all experiments as it partly inhibits the uptake of LPs (Duzgune et al., 1999) . Results showed LP-associated fluorescence in HCE cells immediately, 24, 48, and 72 h after 60 min of exposure. Immediately after the exposure period, the cells had nanometersized dots, indicating that the LP did not aggregate in the formulation. Moreover, these dots corresponding to LPs are within the cell membranes and in the cytosol, as determined by Z-axis micrographs. This documents the efficient interaction of the LPs with the cultured cells and confirmed fast uptake by HCE cells in vitro.
To mimic actual in vivo exposure times, C6-LP was in contact with corneal tissues for only 5 min (Davies, 2000) . After C6-LP exposure, the corneas showed fluorescence through the stratified epithelium, including the basal layers. After 60 min of C6-LP exposure, the corneal stroma was also stained. We therefore demonstrated that LP formulation was taken up by all epithelial layers and reached the corneal stroma after longer exposure times. MPA binds to progesterone, glucocorticoid, androgen, mineralocorticoid, and estrogen receptors (Sitruk-Ware, 2004) . For this study, we analyzed changes in protein expression and nuclear translocation of the glucocorticoid and progesterone receptors, which have greater affinity for the drug (Sitruk-Ware, 2004) . Glucocorticoid and progesterone receptors are closely related members of the steroid receptor family, which act as ligandactivated transcription factors with well-characterized mechanisms of action. After binding a specific ligand, the receptors dimerize, and the dimers are then translocated to the nucleus, allowing the ligand-receptor complex to target specific DNA sequences (hormone response elements), affecting the inflammatory signaling cascade (Mangelsdorf et al., 1995) . We calculated the percentage of glucocorticoid and progesterone receptors translocated to the nucleus in immunofluorescence micrographs as an indicator of receptor activation. Our results showed that while changes in nuclear translocation were observed immediately after the exposure time, the protein expression did not change at this time point and the effect of the drug was observed after 24 h of the exposure time. The progesterone receptor was activated after MPA-LP exposure, suggesting that MPA was released into cells. The translocation and the increased expression of the progesterone receptor, but not the glucocorticoid receptor, after MPA-LP exposure agrees with a study reporting a higher affinity of MPA for the progesterone receptor than for the glucocorticoid receptor (SitrukWare, 2004) . Unexpectedly, the protein expression of glucocorticoid receptor was decreased 24 h after reference formulation exposure. This effect may be due to the vasoconstrictor or the different excipients included in this formulation which interacts with the glucocorticoid receptor and can modify the expression of this receptor. It also could explain the lesser effect observed in proliferation or inflammation experiments. However, the analysis of the effect caused by those excipients is out of the scope of this study and more experiments need to be done to clarify this effect.
Corticosteroids affect in vitro cell proliferation; therefore, we analyzed changes in HCE cell proliferation using a standard proliferation assay. In previous studies, MPA reduced breast cancer epithelial cell proliferation (Cops et al., 2008; Sutherland et al., 1988) , but did not affect corneal fibroblast proliferation (Zhou et al., 2012) . Our findings showed a decrease in the proliferation rate of HCE cells 48 h after MPA exposure, which further supports efficient MPA transport by the LP formulation to the cells.
To determine the anti-inflammatory effect of MPA-LP in terms of reduction of IL-6 and/or IL-8 production, we optimized a cytokineinduced inflammation model using HCE cells. TNFa was used as an inflammatory stimulus, and the cytokine IL-6 and the chemokine IL-8 were used as inflammatory markers. The production of both inflammatory markers increased after TNFa stimulation in conjunctival epithelial cell line (Enriquez-de-Salamanca et al., 2008) , and both are increased in the tears of patients with inflammatory diseases (Lam et al., 2009; Massingale et al., 2009 ). The production of both cytokines was analyzed 48 h after the exposure of TNFa. This time point was chosen because changes in the cell proliferation rate emerged 48 h after the MPA-LP exposure period, with C6-LP-associated fluorescence in the cells. Furthermore, a previous report using corneal fibroblasts showed MPA-induced collagen degradation after 36 h of exposure period (Zhou et al., 2012) . To rule out a pro-inflammatory effect induced by components of the liposomal formulation (Joffre et al., 2007; Rodriguez and Larrayoz, 2010) , blank LP formulation with different cholesterol concentrations were tested, and no inflammation-associated effects were present (data not shown). According to our data, the exposure of MPA-LP and the reference formulation (Medrivas ® ) reduced IL-6 production by HCE cells. However, only MPA-LP reduced IL-8 production. Interestingly, blank LP formulation also reduced IL-8 production in comparison to the reference formulation-treated cells and control cells, although the latter did not reach significance. This result confirms the importance of a vehicle in drug administration, not only to protect the drug and increase the residence time in the ocular surface, but also to enhance therapeutic effect of the drug. This is in agreement with previous data reporting that components of the blank LP formulation, such as PC, trehalose, and vitamin E down-regulate IL-8 production of different epithelial cells in vitro (Cejkova et al., 2011; Ekstrand-Hammarstrom et al., 2007; Elisia and Kitts. 2015; Treede et al., 2009) . Although the in vitro and ex vivo results obtained with MPA-LP are promising, only in vivo experiments can evaluate the effect of physiological mechanisms such as the stress generated by eyelid wiping and tear flow on the liposomal formulation. In addition, the reference formulation (Medrivas ® ) contains not only the preservative BAC but also a vasoconstrictor, tetryzoline chlorhydrate, which might have effects that could not be assessed with our current in vitro approach.
Conclusions
To conclude, our findings show that an anti-inflammatory agent such as MPA loaded in the LP formulation permeated ex vivo through corneal barriers and was efficiently delivered to corneal epithelial cells. Also, the delivered MPA in vitro activated specific drug receptors and showed anti-proliferative and antiinflammatory effects in HCE cells. Consequently, when applied topically as eyedrops, MPA-LP may attach to the hydrophobic corneal epithelium and continuously release the encapsulated drug, improving its biodistribution. In addition, the liposomal formulation does not contain preservatives or other bioactive Fig. 7 . Changes in inflammatory cytokine production in inflamed human corneal epithelial cells. MPA-LP-exposed cells reduced IL-6 and IL-8 production compared with control and blank LP-exposed cells 48 h after the exposure period as determined by ELISA. Note the difference in scales for the y-axes of panels A and B. *P 0.05; **P 0.01; ***P 0.001, compared with control, if not otherwise indicated by straddle bars. LP: liposome-based formulation; MPA-LP: liposome-based formulation loaded with medroxyprogesterone acetate; IL: interleukin; TNFa: tumor necrosis factor-alpha. agents required in the reference formulation, thus avoiding harmful side effects. In this sense, anti-inflammatory drugs included in unpreserved artificial tears can be useful for the treatment of inflammatory processes associated with DED or other ocular surface disorders that involve any inflammatory surface reactions.
